* Health Catalyst Inc HCAT.OQ HCAT.O is expected to show
a
rise in quarterly revenue when it reports results on November 6
for the period ending September 30 2024
* The South Jordan Utah-based company is expected to report
a
3.4% increase in revenue to $76.301 million from $73.77 million
a year ago, according to the mean estimate from 14 analysts,
based on LSEG data.The company's guidance on August 7 2024, for
the period ended September 30, was for revenue between $74.50
million and $77.50 million.
* LSEG's mean analyst estimate for Health Catalyst Inc is
for
earnings of 10 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Health
Catalyst
Inc is $11.00, above its last closing price of $7.70.
The company's guidance on August 7 2024 for the period ended
September 30 was for Earnings before Interest, Taxes,
Depreciation and Amortization of between USD74.5 million and
USD8 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 0.09 0.08 0.12 Beat 51.3
Mar. 31 2024 0.03 0.03 0.05 Beat 79
Dec. 31 2023 0.01 0.00 0.02 Beat 2,700
Sep. 30 2023 0.00 -0.02 0.03 Beat 275.6
Jun. -0.01 0.00 0.05 Beat 1,447.
30 2023 7
Mar. 31 2023 -0.04 -0.04 0.05 Beat 222.9
Dec. 31 2022 -0.11 -0.11 -0.05 Beat 55.8
Sep. 30 2022 -0.18 -0.19 -0.13 Beat 32.8
This summary was machine generated November 4 at 22:05 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)